Medications

First biosimilar approved to treat multiple sclerosis

The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced Thursday.

page 8 from 40